• Exelixis Inc., of South San Francisco, reported preliminary data from a Phase Ib drug interaction trial of cabozantinib in renal cell carcinoma, showing a high rate of durable tumor response, with a low rate of primary refractoriness to drug therapy, and a long median progression-free survival.